Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2002
04/17/2002CN1344743A Human testicular development specific protein-26 gene encoding protein
04/17/2002CN1344742A Human testicualr development specific protein-24 gene encoding protein
04/17/2002CN1344741A Human testicular development specific protein-21 gene encoding protein
04/17/2002CN1344740A Human testicular development specific protein-20 gene encoding protein
04/17/2002CN1344739A Human testicular development specific protein-20B gene encoding protein
04/17/2002CN1344738A Human testicular development specific protein-18 gene encoding protein
04/17/2002CN1344737A Human testicular development specific protein-5 gene encoding protein
04/17/2002CN1344736A 9-0-acetyl esterase gene encoding protein
04/17/2002CN1344735A Human testicular development specific protein-19 gene encoding protein
04/17/2002CN1344564A Prepn of polymyxin E sulfate injection
04/17/2002CN1082795C Feed and feed additive for crustacean
04/16/2002US6372899 Purified genes encoding mammalian cell surface antigens; proteins and antibodies
04/16/2002US6372896 Kits for detecting fOHY030
04/16/2002US6372892 Interleukin—1 Hy2 materials and methods
04/16/2002US6372890 Water-soluble polypeptides
04/16/2002US6372888 Useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications
04/16/2002US6372887 Used to protect an animal from flea infestation
04/16/2002US6372886 Useful for expression of the kringle domains and to the production of antibodies to human lipoprotein
04/16/2002US6372883 For therapy and prophylaxis of infections caused by hepatitis c, hepatitis g and human gb viruses
04/16/2002US6372794 Antiarthritic agents
04/16/2002US6372784 Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
04/16/2002US6372778 Sulfonamide inhibitors of aspartyl protease
04/16/2002US6372744 β-sheet mimetics and methods relating to the use thereof
04/16/2002US6372726 Methods of cancer treatment using NAALADase inhibitors
04/16/2002US6372717 Acylated tyrosine-arginine dipeptide; applying skin lotion topically; sensitivity; analgesics, wound healing agents
04/16/2002US6372716 Freeze dried mixture with glycine, polysorbate, sucrose, and histidine; storage stability
04/16/2002US6372715 Use of erythropoientin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases
04/16/2002US6372713 Administering peptide to relieve stress; side effect reduction
04/16/2002US6372712 Complex of peptidyl-propyl cis/trans isomerase and drug such as rapamycin, cyclosporin a, fk-506, or other antibiotic
04/16/2002US6372711 Receptor binding assay using polypeptide have contiguous sequence of extracellular domain or polypeptide mutein genetically engineered by insertion, deletion, or replacement
04/16/2002US6372501 Glucose responsive β-cell line
04/16/2002US6372494 Culturing fibroblast cells in three-dimensions in a cell culture medium; removing conditioned medium from the cultured cells; combining conditioned medium with a pharmaceutically acceptable carrier
04/16/2002US6372493 Hormone-secreting cells maintained in long-term culture
04/16/2002US6372492 Antisense modulation of talin expression
04/16/2002US6372490 Nucleic acid encoding the MDM interacting protein
04/16/2002US6372488 AMPA-binding human GluR4 receptors
04/16/2002US6372487 Polynucleotides encoding peptide release factor, prfC (RF-3), a GTP-binding protein
04/16/2002US6372474 To deacylate the acyl side chain of a cyclic lipopeptide compound
04/16/2002US6372473 Tissue plasminogen activator-like protease
04/16/2002US6372471 Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon
04/16/2002US6372468 Useful in the development of human therapeutics and diagnostic formulations
04/16/2002US6372456 In diagnosis methods for detecting central nervous system and immune system-related disorders and in therapy
04/16/2002US6372454 Also vectors, host cells; screening methods for identifying agonists or antagonists of follistatin-3 activity; diagnostic methods for detecting reproductive system and cell differentiation disorders and treating these
04/16/2002US6372453 Neurturin receptor
04/16/2002US6372452 Process for obtaining plant peptones with a high hydrolysis degree and applications thereof
04/16/2002US6372443 Cassette for expressing a toxoplasma gondii P30 protein
04/16/2002US6372441 Detecting the expression of the variable exon v10 in the cd44 gene in a patient or in a sample obtained from a patient, wherein the expression of the variable exon v10 in the cd44 gene indicates hodgkin's lymphomas
04/16/2002US6372438 Obtaining transformed mammalian cells comprising a recombinant nucleic acid encoding a hpdgf-r polypeptide; incubating transformed mammalian cells with compound, and incubating witout compound; comparing activation in test cells
04/16/2002US6372433 Antisense modulation of inhibitor of DNA binding-1 expression
04/16/2002US6372431 Mammalian toxicological response markers
04/16/2002US6372427 Cooperative oligonucleotides
04/16/2002US6372264 Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
04/16/2002US6372263 Extracted from fertilized ovum of a sea water fish or a fresh water fish
04/16/2002US6372262 Serum-derived factor inducing cell differentiation and medical uses thereof
04/16/2002US6372260 Incorporation of active substances in carrier matrixes
04/16/2002US6372258 Methods of spray-drying a drug and a hydrophobic amino acid
04/16/2002US6372257 Compositions and methods for forming and strengthening bone
04/16/2002US6372250 Non-invasive gene targeting to the brain
04/16/2002US6372249 Senscent cell-derived inhibitors of DNA synthesis
04/16/2002US6372229 Curing water soluble proteinaceous material and di- or polyaldehyde
04/16/2002US6372228 Method of producing elastin, elastin-based biomaterials and tropoelastin materials
04/16/2002US6372226 Intrathecal administration to a human patient of a neurotoxin such as botulinum toxin type a
04/16/2002US6372224 Vaccine from isolated s protein
04/16/2002US6372219 Parasite-derived anti-inflammatory immunomodulatory protein
04/16/2002US6372218 Interferon dosage form and method therefor
04/16/2002US6372217 Methods for the treatment of CD7+ viral infection with TXU-7-PAP
04/16/2002US6372216 Hyperconcentration of hepatitis virus c neutralizing antibodies
04/16/2002US6372215 Monoclonal antibodies to human CD6
04/16/2002US6372213 Method of treating sickle cell disease or thalassemia
04/16/2002US6372212 Chitinase materials and methods
04/16/2002US6372207 IFNAR2/IFN complex
04/16/2002US6372206 Orally-administered interferon-TAU compositions and methods
04/16/2002US6371992 Acellular matrix grafts: preparation and use
04/16/2002US6371975 Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
04/16/2002CA2359650A1 Pharmaceutical preparations and methods for inhibiting tumors
04/16/2002CA2355334A1 Pharmaceutical preparations and methods for inhibiting tumors
04/16/2002CA2321256A1 Pharmaceutical preparations and methods for inhibiting tumours
04/16/2002CA2217565C Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor (gdnf) protein product
04/16/2002CA2184195C Screening method for identifying ligands for target proteins
04/16/2002CA2115644C Duplex printer
04/16/2002CA2088980C Pro-drugs for cck antagonists
04/16/2002CA2046607C Inhibiting transformation of cells having elevated purine metabolic enzyme activity
04/13/2002CA2321189A1 Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof
04/11/2002WO2002029403A1 Gata-3 expression inhibitor and method of screening the same
04/11/2002WO2002029105A1 INHIBITION OF TGF-β AND USES THEREOF
04/11/2002WO2002029098A2 Genetic factors affecting the outcome of viral infections
04/11/2002WO2002029088A2 Highly expressible genes
04/11/2002WO2002029086A2 Nucleic acid sequences differentially expressed in cancer tissue
04/11/2002WO2002029084A2 Industrial-scale serum-free production of recombinant factor vii in mammalian cells
04/11/2002WO2002029083A2 Industrial-scale serum-free production of recombinant proteins in mammalian cells
04/11/2002WO2002029072A2 Targetting molecules for adenoviral vectors
04/11/2002WO2002029066A1 Antisense inhibition of caspase 6 expression
04/11/2002WO2002029061A2 G-protein coupled receptors
04/11/2002WO2002029060A2 Hematopoietin receptors hpr1 and hpr2
04/11/2002WO2002029059A2 Nogo receptor homologs
04/11/2002WO2002029058A2 Human proteins, polynucleotides encoding them and methods of using the same
04/11/2002WO2002029055A2 Carbohydrate-associated proteins
04/11/2002WO2002029053A1 Novel g protein-coupled receptor protein and dna thereof
04/11/2002WO2002029052A2 Regulation of human secretin receptor-like gpcr
04/11/2002WO2002029051A2 Human secretin receptor-like gpcr